{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:31:21Z","timestamp":1793892681352,"version":"4.8.0"},"reference-count":265,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["No. RS-2023-00207920"],"award-info":[{"award-number":["No. RS-2023-00207920"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01744-9","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:27:39Z","timestamp":1761564459000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?"],"prefix":"10.1186","volume":"18","author":[{"given":"Manh-Cuong","family":"Vo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van-Dinh-Huan","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van-Tan","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nodirjon","family":"Ruzimurodov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dung Tran","family":"Trung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Ki","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"6","key":"1744_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27892","volume":"10","author":"MC Vo","year":"2024","unstructured":"Vo MC, Jung SH, Nguyen VT, Tran VD, Ruzimurodov N, et al. Exploring cellular immunotherapy platforms in multiple myeloma. Heliyon. 2024;10(6):e27892. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e27892.","journal-title":"Heliyon"},{"key":"1744_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","volume":"31","author":"M Sheykhhasan","year":"2024","unstructured":"Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, Zang L, Li D, et al. CAR T therapies in multiple myeloma: Unleashing the future. Cancer Gene Ther. 2024;31:667\u201386. https:\/\/doi.org\/10.1038\/s41417-024-00750-2.","journal-title":"Cancer Gene Ther"},{"key":"1744_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01856-7","volume":"9","author":"B Liu","year":"2024","unstructured":"Liu B, Zhou H, Tan L, Siu KT, Guan XY. Exploring treatment options in cancer: tumor treatment strategies. Sig Transduct Target Ther. 2024;9:175. https:\/\/doi.org\/10.1038\/s41392-024-01856-7.","journal-title":"Sig Transduct Target Ther"},{"key":"1744_CR4","unstructured":"U.S. Food and Drug Administration. FDA approves tisagenlecleucel for B-cell ALL and tocilizumab for cytokine release syndrome. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tisagenlecleucel-b-cell-all-and-tocilizumab-cytokine-release-syndrome."},{"issue":"6","key":"1744_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol. 2023;20(6):359\u201371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"1744_CR6","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol. 2024;21(10):1089\u2013108. https:\/\/doi.org\/10.1038\/s41423-024-01207-0.","journal-title":"Cell Mol Immunol"},{"key":"1744_CR7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","volume":"31","author":"NA Vitanza","year":"2025","unstructured":"Vitanza NA, Ronsley R, Choe M, Seidel K, Huang W, et al. Intracerebroventricular B7\u2013H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat Med. 2025;31:861\u20138. https:\/\/doi.org\/10.1038\/s41591-024-03451-3.","journal-title":"Nat Med"},{"key":"1744_CR8","unstructured":"Cowen L. Pivotal trial of CAR-T cell therapy shows promising results in gastric cancers. Inside Precision Medicine. Oncology. https:\/\/www.insideprecisionmedicine.com\/topics\/oncology\/pivotal-trial-of-car-t-cell-therapy-shows-promising-results-in-gastric-cancers\/."},{"issue":"10494","key":"1744_CR9","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","volume":"405","author":"C Qi","year":"2025","unstructured":"Qi C, Liu C, Peng Z, Zhang Y, Wei J, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025;405(10494):2049\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(25)00860-8.","journal-title":"Lancet"},{"key":"1744_CR10","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Liu M, Fraietta JA, Wang X, Desai AS, et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13R\u03b12 in recurrent glioblastoma: Phase 1 trial interim results. Nat Med. 2024;30:1320\u20139. https:\/\/doi.org\/10.1038\/s41591-024-02893-z.","journal-title":"Nat Med"},{"key":"1744_CR11","unstructured":"Raeke M. Dual-target CAR T cell therapy slows growth of aggressive brain cancer. https:\/\/www.pennmedicine.org\/news\/dual-target-car-t-cell-therapy-slows-growth-of-aggressive-brain-cancer."},{"key":"1744_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01689-z","volume":"18","author":"P Yang","year":"2025","unstructured":"Yang P, Li Z, Chen X, et al. Non-canonical small noncoding RNAs in the plasma extracellular vesicles as novel biomarkers in gastric cancer. J Hematol Oncol. 2025;18:39. https:\/\/doi.org\/10.1186\/s13045-025-01689-z.","journal-title":"J Hematol Oncol"},{"key":"1744_CR13","unstructured":"U.S. Food and Drug Administration. KYMRIAH. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah."},{"key":"1744_CR14","unstructured":"Novartis, Kymriah\u00ae (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r\/r patients with large B-cell lymphoma. https:\/\/www.novartis.com\/us-en\/news\/media-releases\/kymriah-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-B-cell-lymphoma."},{"key":"1744_CR15","unstructured":"U.S. Food and Drug Administration. FDA approves axicabtagene ciloleucel for large B-cell lymphoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-axicabtagene-ciloleucel-large-b-cell-lymphoma."},{"issue":"21","key":"1744_CR16","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1158\/1078-0432.CCR-23-0568","volume":"29","author":"P Sharma","year":"2023","unstructured":"Sharma P, Kasamon YL, Lin X, Xu Z, Theoret MR, et al. FDA approval summary: Axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma. Clin Cancer Res. 2023;29(21):4331\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0568.","journal-title":"Clin Cancer Res"},{"key":"1744_CR17","unstructured":"U.S. Food and Drug Administration. FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma."},{"key":"1744_CR18","unstructured":"National Cancer Institute. CAR T-Cell therapy approved by FDA for mantle cell lymphoma. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2020\/fda-brexucabtagene-mantle-cell-lymphoma."},{"key":"1744_CR19","unstructured":"U.S. Food and Drug Administration. FDA approves lisocabtagene maraleucel for relapsed or refractory large B-cell lymphoma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-large-b-cell-lymphoma."},{"key":"1744_CR20","unstructured":"Canadian Agency for Drugs and Technologies in Health. Lisocabtagene Maraleucel (Breyanzi). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK603593\/?report=classic."},{"key":"1744_CR21","unstructured":"U.S. Food and Drug Administration. FDA approves idecabtagene vicleucel for multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma."},{"issue":"9","key":"1744_CR22","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","volume":"28","author":"P Sharma","year":"2022","unstructured":"Sharma P, Kanapuru B, George B, Lin X, Xu Z, et al. FDA approval summary: Idecabtagene vicleucel for relapsed or refractory multiple myeloma. Clin Cancer Res. 2022;28(9):1759\u201364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3803.","journal-title":"Clin Cancer Res"},{"key":"1744_CR23","unstructured":"U.S. Food and Drug Administration. CARVYKTI. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/carvykti."},{"key":"1744_CR24","doi-asserted-by":"publisher","first-page":"991092","DOI":"10.3389\/fimmu.2022.991092","volume":"13","author":"E Chekol Abebe","year":"2022","unstructured":"Chekol Abebe E, Yibeltal Shiferaw M, Tadele Admasu F, Asmamaw DT. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Front Immunol. 2022;13:991092. https:\/\/doi.org\/10.3389\/fimmu.2022.991092.","journal-title":"Front Immunol"},{"key":"1744_CR25","unstructured":"U.S. Food and Drug Administration. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma."},{"key":"1744_CR26","unstructured":"National Cancer Institute. Carvykti approval marks second CAR T-Cell therapy for multiple myeloma. https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2022\/fda-carvykti-multiple-myeloma."},{"key":"1744_CR27","unstructured":"U.S. Food and Drug Administration. FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute."},{"issue":"3","key":"1744_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s40291-025-00771-z","volume":"29","author":"A Lee","year":"2025","unstructured":"Lee A. Obecabtagene autoleucel: First approval. Mol Diagn Ther. 2025;29(3):419\u201323. https:\/\/doi.org\/10.1007\/s40291-025-00771-z.","journal-title":"Mol Diagn Ther"},{"issue":"5","key":"1744_CR29","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2217\/imt.15.6","volume":"7","author":"HJ Pegram","year":"2015","unstructured":"Pegram HJ, Smith EL, Rafiq S, Brentjens RJ. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies? Immunotherapy. 2015;7(5):545\u201361. https:\/\/doi.org\/10.2217\/imt.15.6.","journal-title":"Immunotherapy"},{"issue":"1","key":"1744_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol. 2020;13(1):125. https:\/\/doi.org\/10.1186\/s13045-020-00962-7.","journal-title":"J Hematol Oncol"},{"issue":"8","key":"1744_CR31","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.medj.2022.05.001","volume":"3","author":"F Korell","year":"2022","unstructured":"Korell F, Berger TR, Maus MV. Understanding CAR T cell-tumor interactions: paving the way for successful clinical outcomes. Med. 2022;3(8):538\u201364. https:\/\/doi.org\/10.1016\/j.medj.2022.05.001.","journal-title":"Med."},{"key":"1744_CR32","unstructured":"National Cancer Institute. CAR T cells: Engineering patients\u2019 immune cells to treat their cancers. https:\/\/www.cancer.gov\/about-cancer\/treatment\/research\/car-t-cells#:~:text=In%20contrast%20to%20the%20advances,them%20from%20reaching%20the%20tumor."},{"key":"1744_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20:49\u201362. https:\/\/doi.org\/10.1038\/s41571-022-00704-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"1744_CR34","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","volume":"35","author":"JL Hsu","year":"2016","unstructured":"Hsu JL, Hung MC. The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev. 2016;35:575\u201388. https:\/\/doi.org\/10.1007\/s10555-016-9649-6.","journal-title":"Cancer Metastasis Rev"},{"key":"1744_CR35","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/sj.bjc.6602738","volume":"93","author":"J Zidan","year":"2005","unstructured":"Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, et al. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005;93:552\u20136. https:\/\/doi.org\/10.1038\/sj.bjc.6602738.","journal-title":"Br J Cancer"},{"key":"1744_CR36","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.canlet.2017.06.024","volume":"403","author":"J Yang","year":"2017","unstructured":"Yang J, Yan J, Liu B. Targeting EGFRvIII for glioblastoma multiforme. Cancer Lett. 2017;403:224\u201330. https:\/\/doi.org\/10.1016\/j.canlet.2017.06.024.","journal-title":"Cancer Lett"},{"issue":"12","key":"1744_CR37","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell Mol Immunol. 2024;21(12):1354\u201375. https:\/\/doi.org\/10.1038\/s41423-024-01226-x.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"1744_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2022.10.013","volume":"41","author":"L Lybaert","year":"2023","unstructured":"Lybaert L, Lefever S, Fant B, Smits E, De Geest B, et al. Challenges in neoantigen-directed therapeutics. Cancer Cell. 2023;41(1):15\u201340. https:\/\/doi.org\/10.1016\/j.ccell.2022.10.013.","journal-title":"Cancer Cell"},{"issue":"4","key":"1744_CR39","doi-asserted-by":"publisher","first-page":"274","DOI":"10.20892\/j.issn.2095-3941.2023.0395","volume":"21","author":"X Li","year":"2023","unstructured":"Li X, You J, Hong L, Liu W, Guo P, et al. Neoantigen cancer vaccines: A new star on the horizon. Cancer Biol Med. 2023;21(4):274\u2013311. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0395.","journal-title":"Cancer Biol Med"},{"key":"1744_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02664","volume":"10","author":"X Xu","year":"2019","unstructured":"Xu X, Sun Q, Liang X, Chen Z, Zhang X, et al. Mechanisms of relapse after CD19 CAR T-cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies. Front Immunol. 2019;10:2664. https:\/\/doi.org\/10.3389\/fimmu.2019.02664.","journal-title":"Front Immunol"},{"issue":"11","key":"1744_CR41","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T cell therapy for solid tumors: bright future or dark reality? Mol Ther. 2020;28(11):2320\u201339. https:\/\/doi.org\/10.1016\/j.ymthe.2020.09.015.","journal-title":"Mol Ther"},{"key":"1744_CR42","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s43018-023-00709-6","volume":"5","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Binder ZA, Lamrani L, Marinari E, Desai AS, et al. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial. Nat Cancer. 2024;5:517\u201331. https:\/\/doi.org\/10.1038\/s43018-023-00709-6.","journal-title":"Nat Cancer"},{"issue":"14","key":"1744_CR43","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, et al. Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma. N Engl J Med. 2024;390(14):1290\u20138. https:\/\/doi.org\/10.1056\/NEJMoa2314390.","journal-title":"N Engl J Med"},{"issue":"399","key":"1744_CR44","doi-asserted-by":"publisher","first-page":"eaaa0984","DOI":"10.1126\/scitranslmed.aaa0984","volume":"9","author":"DM O\u2019Rourke","year":"2017","unstructured":"O\u2019Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. 2017;9(399):eaaa0984. https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984.","journal-title":"Sci Transl Med"},{"issue":"4","key":"1744_CR45","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","volume":"42","author":"SL Goff","year":"2019","unstructured":"Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, et al. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced T cells targeting EGFRvIII in patients with glioblastoma. J Immunother. 2019;42(4):126\u201335. https:\/\/doi.org\/10.1097\/CJI.0000000000000260.","journal-title":"J Immunother"},{"issue":"1","key":"1744_CR46","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41467-020-20785-x","volume":"12","author":"B Moghimi","year":"2021","unstructured":"Moghimi B, Muthugounder S, Jambon S, Tibbetts R, Hung L, et al. Preclinical assessment of the efficacy and specificity of GD2-B7H3 synnotch CAR-T in metastatic neuroblastoma. Nat Commun. 2021;12(1):511. https:\/\/doi.org\/10.1038\/s41467-020-20785-x.","journal-title":"Nat Commun"},{"issue":"1","key":"1744_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","volume":"6","author":"SA Richman","year":"2018","unstructured":"Richman SA, Nunez-Cruz S, Moghimi B, Li LZ, Gershenson ZT, et al. High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer Immunol Res. 2018;6(1):36\u201346. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0211.","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"1744_CR48","first-page":"4660","volume":"61","author":"N Amara","year":"2001","unstructured":"Amara N, Palapattu GS, Schrage M, Gu Z, Thomas GV, et al. Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. Cancer Res. 2001;61(12):4660\u20135 (PMID: 11406532).","journal-title":"Cancer Res"},{"issue":"1","key":"1744_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03320-6","volume":"24","author":"T Nayerpour Dizaj","year":"2024","unstructured":"Nayerpour Dizaj T, Doustmihan A, Sadeghzadeh Oskouei B, Akbari M, Jaymand M, et al. Significance of PSCA as a novel prognostic marker and therapeutic target for cancer. Cancer Cell Int. 2024;24(1):135. https:\/\/doi.org\/10.1186\/s12935-024-03320-6.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"1744_CR50","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/1078-0432.CCR-23-1735","volume":"30","author":"C Qi","year":"2024","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, et al. Intratumoral delivery of chimeric antigen receptor T cells targeting CD133 effectively treats brain metastases. Clin Cancer Res. 2024;30(3):554\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1735.","journal-title":"Clin Cancer Res"},{"key":"1744_CR51","unstructured":"CARsgen Therapeutics Co., Ltd. Study to evaluate the efficacy, safety and pharmacokinetics of CT041 autologous CAR T-cell injection. ClinicalTrials.gov. Identifier: NCT04581473."},{"key":"1744_CR52","unstructured":"CARsgen Therapeutics Co., Ltd. Claudin18.2 CAR-T (CT041) in patients with gastric, pancreatic cancer, or other specified digestive cancers. ClinicalTrials.gov. identifier: NCT04404595."},{"key":"1744_CR53","unstructured":"University of Pennsylvania. Chimeric antigen receptor T cells targeting claudin18.2 in solid tumors. ClinicalTrials.gov. Identifier: NCT03874897."},{"issue":"1","key":"1744_CR54","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","volume":"26","author":"CE Brown","year":"2018","unstructured":"Brown CE, Aguilar B, Starr R, Yang X, Chang WC, et al. Optimization of IL13R\u03b12-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma. Mol Ther. 2018;26(1):31\u201344. https:\/\/doi.org\/10.1016\/j.ymthe.2017.10.002.","journal-title":"Mol Ther"},{"issue":"18","key":"1744_CR55","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","volume":"21","author":"CE Brown","year":"2015","unstructured":"Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, et al. Bioactivity and safety of IL13R\u03b12-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma. Clin Cancer Res. 2015;21(18):4062\u201372. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0428.","journal-title":"Clin Cancer Res"},{"issue":"33","key":"1744_CR56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2112006119","volume":"119","author":"LA Stern","year":"2022","unstructured":"Stern LA, Gholamin S, Moraga I, Yang X, Saravanakumar S, et al. Engineered IL13 variants direct specificity of IL13R\u03b12-targeted CAR T cell therapy. Proc Natl Acad Sci U S A. 2022;119(33):e2112006119. https:\/\/doi.org\/10.1073\/pnas.2112006119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1744_CR57","unstructured":"Sorrento Biopharmaceuticals Ltd. Study of autologous T-cells in patients with metastatic pancreatic cancer. ClinicalTrials.gov. Identifier: NCT03638193."},{"key":"1744_CR58","unstructured":"University of Pennsylvania. Autologous redirected RNA meso CAR T cells for pancreatic cancer. ClinicalTrials.gov. Identifier: NCT01897415."},{"key":"1744_CR59","unstructured":"University of Pennsylvania. CAR T cell immunotherapy for pancreatic cancer. ClinicalTrials.gov. Identifier: NCT03323944."},{"key":"1744_CR60","unstructured":"Roger Williams Medical Center. CEA-expressing liver metastases safety study of intrahepatic infusions of anti-CEA designer T cells (HITM). ClinicalTrials.gov. Identifier: NCT01373047."},{"key":"1744_CR61","unstructured":"Southwest Hospital, China. A clinical research of CAR T cells targeting CEA positive cancer. ClinicalTrials.gov. Identifier: NCT02349724."},{"key":"1744_CR62","unstructured":"The First Affiliated Hospital of Guangdong Pharmaceutical University. Anti-MUC1 CAR T cells and PD-1 knockout engineered T cells for NSCLC. ClinicalTrials.gov. Identifier: NCT03525782."},{"issue":"1","key":"1744_CR63","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1186\/s12951-024-03005-2","volume":"22","author":"Y Feng","year":"2024","unstructured":"Feng Y, Tang Q, Wang B, Yang Q, Zhang Y, et al. Targeting the tumor microenvironment with biomaterials for enhanced immunotherapeutic efficacy. J Nanobiotechnol. 2024;22(1):737. https:\/\/doi.org\/10.1186\/s12951-024-03005-2.","journal-title":"J Nanobiotechnol"},{"issue":"3","key":"1744_CR64","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccell.2017.02.008","volume":"31","author":"KG Anderson","year":"2017","unstructured":"Anderson KG, Stromnes IM, Greenberg PD. Obstacles posed by the tumor microenvironment to T cell activity: a case for synergistic therapies. Cancer Cell. 2017;31(3):311\u201325. https:\/\/doi.org\/10.1016\/j.ccell.2017.02.008.","journal-title":"Cancer Cell"},{"issue":"5","key":"1744_CR65","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","volume":"25","author":"G Guzman","year":"2023","unstructured":"Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A. CAR-T therapies in solid tumors: Opportunities and challenges. Curr Oncol Rep. 2023;25(5):479\u201389. https:\/\/doi.org\/10.1007\/s11912-023-01380-x.","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"1744_CR66","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1744_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01868-3","volume":"9","author":"M Yi","year":"2024","unstructured":"Yi M, Li T, Niu M, Zhang H, Wu Y, et al. Targeting cytokine and chemokine signaling pathways for cancer therapy. Signal Transduct Target Ther. 2024;9(1):176. https:\/\/doi.org\/10.1038\/s41392-024-01868-3.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1744_CR68","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23(1):108. https:\/\/doi.org\/10.1186\/s12943-024-02023-w.","journal-title":"Mol Cancer"},{"issue":"5","key":"1744_CR69","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","volume":"15","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111\u201322. https:\/\/doi.org\/10.1080\/21645515.2019.1571892.","journal-title":"Hum Vaccin Immunother"},{"issue":"200","key":"1744_CR70","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006504","volume":"5","author":"S Spranger","year":"2013","unstructured":"Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5(200):200ra116. https:\/\/doi.org\/10.1126\/scitranslmed.3006504.","journal-title":"Sci Transl Med"},{"issue":"4","key":"1744_CR71","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2217\/imt-2018-0141","volume":"11","author":"A Schurich","year":"2019","unstructured":"Schurich A, Magalhaes I, Mattsson J. Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors. Immunotherapy. 2019;11(4):335\u201345. https:\/\/doi.org\/10.2217\/imt-2018-0141.","journal-title":"Immunotherapy"},{"key":"1744_CR72","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.cmet.2023.07.001","volume":"35","author":"L Wu","year":"2023","unstructured":"Wu L, Jin Y, Zhao X, Tang K, Zhao Y, et al. Tumor aerobic glycolysis confers immune evasion through modulating sensitivity to T cell-mediated bystander killing via TNF-\u03b1. Cell Metab. 2023;35:1580\u201396. https:\/\/doi.org\/10.1016\/j.cmet.2023.07.001.","journal-title":"Cell Metab"},{"key":"1744_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00646-1","volume":"12","author":"H Zhang","year":"2024","unstructured":"Zhang H, Li S, Wang D, Liu S, Xiao T, et al. Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment. Biomark Res. 2024;12:96. https:\/\/doi.org\/10.1186\/s40364-024-00646-1.","journal-title":"Biomark Res"},{"issue":"6","key":"1744_CR74","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.molcel.2020.05.034","volume":"78","author":"JE Bader","year":"2020","unstructured":"Bader JE, Voss K, Rathmell JC. Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy. Mol Cell. 2020;78(6):1019\u201333. https:\/\/doi.org\/10.1016\/j.molcel.2020.05.034.","journal-title":"Mol Cell"},{"issue":"8","key":"1744_CR75","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","volume":"24","author":"CE Brown","year":"2022","unstructured":"Brown CE, Rodriguez A, Palmer J, Ostberg JR, Naranjo A, et al. Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma. Neuro Oncol. 2022;24(8):1318\u201330. https:\/\/doi.org\/10.1093\/neuonc\/noac024.","journal-title":"Neuro Oncol"},{"issue":"11","key":"1744_CR76","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/neuonc\/noz117","volume":"21","author":"J Cui","year":"2019","unstructured":"Cui J, Zhang Q, Song Q, Wang H, Dmitriev P, et al. Targeting hypoxia downstream signaling protein, CAIX, for CAR T-cell therapy against glioblastoma. Neuro Oncol. 2019;21(11):1436\u201346. https:\/\/doi.org\/10.1093\/neuonc\/noz117.","journal-title":"Neuro Oncol"},{"key":"1744_CR77","unstructured":"Seattle Children\u2019s Hospital. EGFR806 CAR T cell immunotherapy for recurrent\/refractory solid tumors in children and young adults. ClinicalTrials.gov. Identifier: NCT03618381."},{"key":"1744_CR78","unstructured":"Baylor College of Medicine. Her2 chimeric antigen receptor expressing T cells in advanced sarcoma. ClinicalTrials.gov. Identifier: NCT00902044."},{"issue":"4","key":"1744_CR79","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: The rosetta stone of therapy resistance. Cancer Cell. 2020;37(4):471\u201384. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.007.","journal-title":"Cancer Cell"},{"key":"1744_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.106964","volume":"159","author":"H Ai","year":"2023","unstructured":"Ai H, Song D, Wang X. Defining multiple layers of intratumor heterogeneity based on variations of perturbations in multi-omics profiling. Comput Biol Med. 2023;159:106964. https:\/\/doi.org\/10.1016\/j.compbiomed.2023.106964.","journal-title":"Comput Biol Med"},{"issue":"1","key":"1744_CR81","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2014.12.001","volume":"27","author":"N McGranahan","year":"2015","unstructured":"McGranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27(1):15\u201326. https:\/\/doi.org\/10.1016\/j.ccell.2014.12.001.","journal-title":"Cancer Cell"},{"issue":"4","key":"1744_CR82","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell. 2017;168(4):613\u201328. https:\/\/doi.org\/10.1016\/j.cell.2017.01.018.","journal-title":"Cell"},{"issue":"2","key":"1744_CR83","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00109-020-01874-2","volume":"98","author":"S Ram\u00f3n Y Cajal","year":"2020","unstructured":"Ram\u00f3n Y Cajal S, Ses\u00e9 M, Capdevila C, Aasen T, De Mattos-Arruda L, et al. Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med (Berl). 2020;98(2):161\u201377. https:\/\/doi.org\/10.1007\/s00109-020-01874-2.","journal-title":"J Mol Med (Berl)"},{"issue":"14","key":"1744_CR84","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1158\/1078-0432.CCR-21-1355","volume":"28","author":"Y Wolf","year":"2022","unstructured":"Wolf Y, Samuels Y. Intratumor heterogeneity and antitumor immunity shape one another bidirectionally. Clin Cancer Res. 2022;28(14):2994\u20133001. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1355.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1744_CR85","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41571-019-0184-6","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372\u201385. https:\/\/doi.org\/10.1038\/s41571-019-0184-6.","journal-title":"Nat Rev Clin Oncol"},{"key":"1744_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107302","volume":"206","author":"Z Tuo","year":"2024","unstructured":"Tuo Z, Zhang Y, Li D, Wang Y, Wu R, et al. Relationship between clonal evolution and drug resistance in bladder cancer: a genomic research review. Pharmacol Res. 2024;206:107302. https:\/\/doi.org\/10.1016\/j.phrs.2024.107302.","journal-title":"Pharmacol Res"},{"key":"1744_CR87","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med. 2017;376:2109\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1616288.","journal-title":"N Engl J Med"},{"issue":"7","key":"1744_CR88","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nm.3886","volume":"21","author":"LR Yates","year":"2015","unstructured":"Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015;21(7):751\u20139. https:\/\/doi.org\/10.1038\/nm.3886.","journal-title":"Nat Med"},{"issue":"4","key":"1744_CR89","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ccell.2019.02.007","volume":"35","author":"V K\u00f6rber","year":"2019","unstructured":"K\u00f6rber V, Yang J, Barah P, Wu Y, Stichel D, et al. Evolutionary trajectories of IDHWT glioblastomas reveal a common path of early tumorigenesis instigated years ahead of initial diagnosis. Cancer Cell. 2019;35(4):692-704.e12. https:\/\/doi.org\/10.1016\/j.ccell.2019.02.007.","journal-title":"Cancer Cell"},{"key":"1744_CR90","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ebiom.2019.01.050","volume":"40","author":"DS Bhullar","year":"2019","unstructured":"Bhullar DS, Barriuso J, Mullamitha S, Saunders MP, O\u2019Dwyer ST, et al. Biomarker concordance between primary colorectal cancer and its metastases. EBioMedicine. 2019;40:363\u201374. https:\/\/doi.org\/10.1016\/j.ebiom.2019.01.050.","journal-title":"EBioMedicine"},{"issue":"6280","key":"1744_CR91","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463\u20139. https:\/\/doi.org\/10.1126\/science.aaf1490.","journal-title":"Science"},{"key":"1744_CR92","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1200\/EDBK_158808","volume":"35","author":"CM Lovly","year":"2016","unstructured":"Lovly CM, Salama AK, Salgia R. Tumor heterogeneity and therapeutic resistance. Am Soc Clin Oncol Educ Book. 2016;35:e585\u201393. https:\/\/doi.org\/10.1200\/EDBK_158808.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1744_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00227","volume":"4","author":"G Turashvili","year":"2017","unstructured":"Turashvili G, Brogi E. Tumor heterogeneity in breast cancer. Front Med Lausanne. 2017;4:227. https:\/\/doi.org\/10.3389\/fmed.2017.00227.","journal-title":"Front Med Lausanne"},{"issue":"7","key":"1744_CR94","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/j.cell.2024.02.041","volume":"187","author":"A Passaro","year":"2024","unstructured":"Passaro A, Al Bakir M, Hamilton EG, Diehn M, Andr\u00e9 F, et al. Cancer biomarkers: emerging trends and clinical implications for personalized treatment. Cell. 2024;187(7):1617\u201335. https:\/\/doi.org\/10.1016\/j.cell.2024.02.041.","journal-title":"Cell"},{"issue":"1","key":"1744_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01848-7","volume":"9","author":"S Zhang","year":"2024","unstructured":"Zhang S, Xiao X, Yi Y, Wang X, Zhu L, et al. Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets. Sig Transduct Target Ther. 2024;9(1):149. https:\/\/doi.org\/10.1038\/s41392-024-01848-7.","journal-title":"Sig Transduct Target Ther"},{"issue":"1","key":"1744_CR96","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1073\/pnas.0908428107","volume":"107","author":"JP Morton","year":"2010","unstructured":"Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, et al. Mutant p53 drives metastasis and overcomes growth arrest\/senescence in pancreatic cancer. Proc Natl Acad Sci U S A. 2010;107(1):246\u201351. https:\/\/doi.org\/10.1073\/pnas.0908428107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1744_CR97","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.pan.2022.07.010","volume":"22","author":"L Sivapalan","year":"2022","unstructured":"Sivapalan L, Kocher HM, Ross-Adams H, Chelala C. The molecular landscape of pancreatic ductal adenocarcinoma. Pancreatology. 2022;22(7):925\u201336. https:\/\/doi.org\/10.1016\/j.pan.2022.07.010.","journal-title":"Pancreatology"},{"issue":"6","key":"1744_CR98","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.trsl.2015.08.001","volume":"166","author":"JT Chang","year":"2015","unstructured":"Chang JT, Lee YM, Huang RS. The impact of the cancer genome atlas on lung cancer. Transl Res. 2015;166(6):568\u201385. https:\/\/doi.org\/10.1016\/j.trsl.2015.08.001.","journal-title":"Transl Res"},{"issue":"8","key":"1744_CR99","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160\u20137. https:\/\/doi.org\/10.1200\/JCO.2008.18.1370.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1744_CR100","doi-asserted-by":"publisher","first-page":"736540","DOI":"10.3389\/fcell.2021.736540","volume":"9","author":"W Zhong","year":"2021","unstructured":"Zhong W, Li Y, Yuan Y, Zhong H, Huang C, et al. Characterization of molecular heterogeneity associated with tumor microenvironment in clear cell renal cell carcinoma to aid immunotherapy. Front Cell Dev Biol. 2021;9(1):736540. https:\/\/doi.org\/10.3389\/fcell.2021.736540.","journal-title":"Front Cell Dev Biol"},{"issue":"8","key":"1744_CR101","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1303989.","journal-title":"N Engl J Med"},{"issue":"1","key":"1744_CR102","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","volume":"23","author":"X Xia","year":"2024","unstructured":"Xia X, Yang Z, Lu Q, Liu Z, Wang L, et al. Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Mol Cancer. 2024;23(1):175. https:\/\/doi.org\/10.1186\/s12943-024-02079-8.","journal-title":"Mol Cancer"},{"issue":"14","key":"1744_CR103","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.7150\/thno.76854","volume":"12","author":"Z Liu","year":"2022","unstructured":"Liu Z, Zhou Z, Dang Q, Xu H, Lv J, et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics. 2022;12(14):6273\u201390. https:\/\/doi.org\/10.7150\/thno.76854.","journal-title":"Theranostics"},{"issue":"1","key":"1744_CR104","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01625-7","volume":"17","author":"K Ai","year":"2024","unstructured":"Ai K, Liu B, Chen X, Huang C, Yang L, et al. Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies. J Hematol Oncol. 2024;17(1):105. https:\/\/doi.org\/10.1186\/s13045-024-01625-7.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1744_CR105","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao X, Huang S, Chen S, Wang Y, Sun Q, et al. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40(1):367. https:\/\/doi.org\/10.1186\/s13046-021-02148-6.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"1744_CR106","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s44318-024-00319-7","volume":"44","author":"H Estephan","year":"2025","unstructured":"Estephan H, Tailor A, Parker R, Kreamer M, Papandreou I, et al. Hypoxia promotes tumor immune evasion by suppressing MHC-I expression and antigen presentation. EMBO J. 2025;44(3):903\u201322. https:\/\/doi.org\/10.1038\/s44318-024-00319-7.","journal-title":"EMBO J"},{"issue":"1","key":"1744_CR107","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","volume":"84","author":"X Zhu","year":"2024","unstructured":"Zhu X, Chen J, Li W, Xu Y, Shan J, et al. Hypoxia-responsive CAR-T cells exhibit reduced exhaustion and enhanced efficacy in solid tumors. Cancer Res. 2024;84(1):84\u2013100. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-1038.","journal-title":"Cancer Res"},{"key":"1744_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.11","volume":"3","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther. 2016;3:16011. https:\/\/doi.org\/10.1038\/mto.2016.11.","journal-title":"Mol Ther"},{"issue":"1","key":"1744_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0813-7","volume":"12","author":"X Han","year":"2019","unstructured":"Han X, Wang Y, Wei J, Han W. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy. J Hematol Oncol. 2019;12(1):128. https:\/\/doi.org\/10.1186\/s13045-019-0813-7.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"1744_CR110","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1007\/s00262-023-03529-w","volume":"72","author":"SS Mun","year":"2023","unstructured":"Mun SS, Meyerberg J, Peraro L, Korontsvit T, Gardner T, et al. Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1. Cancer Immunol Immunother. 2023;72(11):3773\u201386. https:\/\/doi.org\/10.1007\/s00262-023-03529-w.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1744_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50251-x","volume":"15","author":"M Tian","year":"2024","unstructured":"Tian M, Wei JS, Cheuk AT, Milewski D, Zhang Z, et al. CAR t-cells targeting FGFR4 and CD276 simultaneously show potent antitumor effect against childhood rhabdomyosarcoma. Nat Commun. 2024;15(1):6222. https:\/\/doi.org\/10.1038\/s41467-024-50251-x.","journal-title":"Nat Commun"},{"issue":"4","key":"1744_CR112","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/cas.14799","volume":"112","author":"Z Guo","year":"2021","unstructured":"Guo Z, Tu S, Yu S, Wu L, Pan W, et al. Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies. Cancer Sci. 2021;112(4):1357\u201368. https:\/\/doi.org\/10.1111\/cas.14799.","journal-title":"Cancer Sci"},{"issue":"1","key":"1744_CR113","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac185","volume":"5","author":"A Schmidts","year":"2022","unstructured":"Schmidts A, Srivastava AA, Ramapriyan R, Bailey SR, Bouffard AA, et al. Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13R\u03b12 are effective against heterogeneous glioblastoma. Neuro-Oncology Advances. 2022;5(1):vdac185. https:\/\/doi.org\/10.1093\/noajnl\/vdac185.","journal-title":"Neuro-Oncology Advances"},{"issue":"8","key":"1744_CR114","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, et al. Tandem CAR T cells targeting HER2 and IL13R\u03b12 mitigate tumor antigen escape. J Clin Invest. 2016;126(8):3036\u201352. https:\/\/doi.org\/10.1172\/JCI83416.","journal-title":"J Clin Invest"},{"issue":"3","key":"1744_CR115","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/icb.2014.93","volume":"93","author":"AM Huehls","year":"2015","unstructured":"Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93(3):290\u20136. https:\/\/doi.org\/10.1038\/icb.2014.93.","journal-title":"Immunol Cell Biol"},{"issue":"7","key":"1744_CR116","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","volume":"30","author":"Y Yin","year":"2022","unstructured":"Yin Y, Rodriguez JL, Li N, Thokala R, Nasrallah MP, et al. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. Mol Ther. 2022;30(7):2537\u201353. https:\/\/doi.org\/10.1016\/j.ymthe.2022.05.011.","journal-title":"Mol Ther"},{"key":"1744_CR117","unstructured":"Stanford University. Dual-targeting HER2 and PD-L1 CAR-T for solid tumors. ClinicalTrials.gov. Identifier: NCT04684459."},{"issue":"591","key":"1744_CR118","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8836","volume":"13","author":"A Hyrenius-Wittsten","year":"2021","unstructured":"Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, et al. Synnotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med. 2021;13(591):eabd8836. https:\/\/doi.org\/10.1126\/scitranslmed.abd8836.","journal-title":"Sci Transl Med"},{"key":"1744_CR119","unstructured":"Okada H. Anti-EGFRvIII synNotch receptor induced anti-EphA2\/\u200bIL-13Ralpha2 CAR (E-SYNC) T cells. ClinicalTrials.gov. Identifier: NCT06186401."},{"issue":"591","key":"1744_CR120","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","volume":"13","author":"JH Choe","year":"2021","unstructured":"Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, et al. Synnotch-CAR t cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13(591):eabe7378. https:\/\/doi.org\/10.1126\/scitranslmed.abe7378.","journal-title":"Sci Transl Med"},{"issue":"3","key":"1744_CR121","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","volume":"35","author":"S Srivastava","year":"2019","unstructured":"Srivastava S, Salter AI, Liggitt D, Yechan-Gunja S, Sarvothama M, et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell. 2019;35(3):489-503.e8. https:\/\/doi.org\/10.1016\/j.ccell.2019.02.003.","journal-title":"Cancer Cell"},{"key":"1744_CR122","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1383894","volume":"15","author":"LS Schlegel","year":"2024","unstructured":"Schlegel LS, Werbrouck C, Boettcher M, Schlegel P. Universal CAR 2.0 to overcome current limitations in CAR therapy. Front Immunol. 2024;15:1383894. https:\/\/doi.org\/10.3389\/fimmu.2024.1383894.","journal-title":"Front Immunol"},{"issue":"9","key":"1744_CR123","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41551-023-01048-8","volume":"7","author":"AQ Zhang","year":"2023","unstructured":"Zhang AQ, Hostetler A, Chen LE, Mukkamala V, Abraham W, et al. Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR. Nat Biomed Eng. 2023;7(9):1113\u201328. https:\/\/doi.org\/10.1038\/s41551-023-01048-8.","journal-title":"Nat Biomed Eng"},{"issue":"9","key":"1744_CR124","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166028","volume":"133","author":"JE Jaspers","year":"2023","unstructured":"Jaspers JE, Khan JF, Godfrey WD, Lopez AV, Ciampricotti M, et al. IL-18\u2013secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Invest. 2023;133(9):e166028. https:\/\/doi.org\/10.1172\/JCI166028.","journal-title":"J Clin Invest"},{"issue":"5","key":"1744_CR125","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1021\/acscentsci.2c00163","volume":"8","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Dong Y, Yang S, Tu Y, Wang C, et al. Bioorthogonal equipping CAR-T cells with hyaluronidase and checkpoint blocking antibody for enhanced solid tumor immunotherapy. ACS Cent Sci. 2022;8(5):603\u201314. https:\/\/doi.org\/10.1021\/acscentsci.2c00163.","journal-title":"ACS Cent Sci"},{"issue":"5","key":"1744_CR126","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/eji.201948457","volume":"50","author":"G Liu","year":"2020","unstructured":"Liu G, Rui W, Zheng H, Huang D, Yu F, et al. Cxcr2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur J Immunol. 2020;50(5):712\u201324. https:\/\/doi.org\/10.1002\/eji.201948457.","journal-title":"Eur J Immunol"},{"issue":"3\u20134","key":"1744_CR127","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1089\/hum.2020.278","volume":"32","author":"K McGrath","year":"2021","unstructured":"McGrath K, Dotti G. Combining oncolytic viruses with chimeric antigen receptor T cell therapy. Hum Gene Ther. 2021;32(3\u20134):150\u20137. https:\/\/doi.org\/10.1089\/hum.2020.278.","journal-title":"Hum Gene Ther"},{"issue":"11","key":"1744_CR128","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1016\/j.ymthe.2022.07.021","volume":"30","author":"M Zhou","year":"2022","unstructured":"Zhou M, Chen M, Shi B, Di S, Sun R, et al. Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-\u03baB\/Icam1 signaling. Mol Ther. 2022;30(11):3379\u201393. https:\/\/doi.org\/10.1016\/j.ymthe.2022.07.021.","journal-title":"Mol Ther"},{"key":"1744_CR129","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41587-024-02339-4","volume":"43","author":"T Rakhshandehroo","year":"2025","unstructured":"Rakhshandehroo T, Mantri SR, Moravej H, Louis BBV, Salehi Farid A, et al. A CAR enhancer increases the activity and persistence of CAR T cells. Nat Biotechnol. 2025;43:948\u201359. https:\/\/doi.org\/10.1038\/s41587-024-02339-4.","journal-title":"Nat Biotechnol"},{"key":"1744_CR130","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jconrel.2022.08.033","volume":"350","author":"JE Zhou","year":"2022","unstructured":"Zhou JE, Sun L, Jia Y, Wang Z, Luo T, et al. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo. J Control Release. 2022;350:298\u2013307. https:\/\/doi.org\/10.1016\/j.jconrel.2022.08.033.","journal-title":"J Control Release"},{"issue":"10","key":"1744_CR131","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/d41573-024-00150-z","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard A. In vivo CAR T cells move into clinical trials. Nat Rev Drug Discov. 2024;23(10):727\u201330. https:\/\/doi.org\/10.1038\/d41573-024-00150-z.","journal-title":"Nat Rev Drug Discov"},{"issue":"6753","key":"1744_CR132","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y, Matsuda D, Riener R, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311\u20137. https:\/\/doi.org\/10.1126\/science.ads8473.","journal-title":"Science"},{"key":"1744_CR133","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.809754","volume":"12","author":"T Xin","year":"2022","unstructured":"Xin T, Cheng L, Zhou C, Zhao Y, Hu Z, et al. In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy. Front Oncol. 2022;12:809754. https:\/\/doi.org\/10.3389\/fonc.2022.809754.","journal-title":"Front Oncol"},{"issue":"1","key":"1744_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0460-x","volume":"13","author":"M Koneru","year":"2015","unstructured":"Koneru M, O\u2019Cearbhaill R, Pendharkar S, Spriggs DR, Brentjens RJ. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med. 2015;(1):102. https:\/\/doi.org\/10.1186\/s12967-015-0460-x.","journal-title":"J Transl Med"},{"issue":"11","key":"1744_CR135","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli PS, Zauderer MG, Rivi\u00e8re I, Solomon SB, Rusch VW, et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 2021;11(11):2748\u201363. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0407.","journal-title":"Cancer Discov"},{"issue":"5","key":"1744_CR136","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471\u201382. https:\/\/doi.org\/10.1016\/j.ccell.2019.09.006.","journal-title":"Cancer Cell"},{"key":"1744_CR137","unstructured":"Baylor College of Medicine. 3rd generation GD-2 chimeric antigen receptor and iCaspase suicide safety switch, neuroblastoma, GRAIN (GRAIN). ClinicalTrials.gov. Identifier: NCT01822652."},{"key":"1744_CR138","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00235","volume":"5","author":"T Gargett","year":"2014","unstructured":"Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235. https:\/\/doi.org\/10.3389\/fphar.2014.00235.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1744_CR139","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","volume":"2","author":"GL Beatty","year":"2014","unstructured":"Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112\u201320. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0170.","journal-title":"Cancer Immunol Res"},{"key":"1744_CR140","unstructured":"Myeloid Therapeutics Inc. Myeloid Therapeutics initiates patient dosing with MT-303, a novel GPC3 targeting RNA CAR, in phase 1 study for advanced hepatocellular carcinoma (HCC). PR Newswire. https:\/\/www.prnewswire.com\/news-releases\/myeloid-therapeutics-initiates-patient-dosing-with-mt-303-a-novel-gpc3-targeting-rna-car-in-phase-1-study-for-advanced-hepatocellular-carcinoma-hcc-302210394.html."},{"key":"1744_CR141","doi-asserted-by":"publisher","unstructured":"Argueta S, Melber FK, Gorgievski M, D\u2019Alessandro J, Cochran E et al. Preclinical development of MT-303, a novel LNP-formulated GPC3-specific CAR mRNA, for in vivo programming of monocytes to treat hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. Volume 12, Issue Suppl 2 .https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.1125.","DOI":"10.1136\/jitc-2024-SITC2024.1125"},{"key":"1744_CR142","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","volume":"30","author":"CE Brown","year":"2024","unstructured":"Brown CE, Hibbard JC, Alizadeh D, Blanchard MS, Natri HM, et al. Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial. Nat Med. 2024;30:1001\u201312. https:\/\/doi.org\/10.1038\/s41591-024-02875-1.","journal-title":"Nat Med"},{"key":"1744_CR143","unstructured":"Wang LD; City of Hope, Beckman Research Institute. Phase I study of IL13R\u03b12-targeting CAR T cells after lymphodepletion for children with refractory or recurrent malignant brain tumors. https:\/\/www.cirm.ca.gov\/our-progress\/awards\/phase-i-study-il13r%CE%B12-targeting-car-t-cells-after-lymphodepletion-children-refractory-or-recurrent-malignant-brain-tumors\/."},{"key":"1744_CR144","unstructured":"City of Hope Medical Center. Memory-enriched T cells in treating patients with recurrent or refractory grade III-IV glioma. ClinicalTrials.gov. Identifier: NCT03389230."},{"issue":"690","key":"1744_CR145","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abk1900","volume":"15","author":"D Meyran","year":"2023","unstructured":"Meyran D, Zhu JJ, Butler J, Tantalo D, MacDonald S, et al. TSTEM-like CAR-T cells exhibit improved persistence and tumor control compared with conventional CAR-T cells in preclinical models. Sci Transl Med. 2023;15(690):eabk1900. https:\/\/doi.org\/10.1126\/scitranslmed.abk1900.","journal-title":"Sci Transl Med"},{"issue":"2","key":"1744_CR146","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44(2):380\u201390. https:\/\/doi.org\/10.1016\/j.immuni.2016.01.021.","journal-title":"Immunity"},{"issue":"9","key":"1744_CR147","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.cell.2025.03.017","volume":"188","author":"T Kondo","year":"2025","unstructured":"Kondo T, Bourassa FXP, Achar S, DuSold J, C\u00e9spedes PF, et al. Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity. Cell. 2025;188(9):2372-2389.e35. https:\/\/doi.org\/10.1016\/j.cell.2025.03.017.","journal-title":"Cell"},{"issue":"6_suppl","key":"1744_CR148","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.094","volume":"40","author":"M McKean","year":"2022","unstructured":"McKean M, Carabasi MH, Stein MN, Schweizer MT, Luke JJ, et al. Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC. J Clin Oncol. 2022;40(6_suppl):94. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.094.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1744_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 2023;12(1):14. https:\/\/doi.org\/10.1186\/s40164-023-00373-7.","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"1744_CR150","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000542438","volume":"52","author":"LT Tony","year":"2025","unstructured":"Tony LT, Stabile A, Schauer MP, Hudecek M, Weber J. CAR-T cell therapy for solid tumors. Transfus Med Hemother. 2025;52(1):96\u2013108. https:\/\/doi.org\/10.1159\/000542438.","journal-title":"Transfus Med Hemother"},{"issue":"2","key":"1744_CR151","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s12519-025-00876-9","volume":"21","author":"PT Ying","year":"2025","unstructured":"Ying PT, Tang YM. Challenges and overcoming strategies in CAR-T cell therapy for pediatric neuroblastoma. World J Pediatr. 2025;21(2):123\u201330. https:\/\/doi.org\/10.1007\/s12519-025-00876-9.","journal-title":"World J Pediatr"},{"issue":"1","key":"1744_CR152","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1158\/1078-0432.CCR-13-1016","volume":"20","author":"SK Perna","year":"2014","unstructured":"Perna SK, Pagliara D, Mahendravada A, Liu H, Brenner MK, et al. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res. 2014;20(1):131\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1016.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1744_CR153","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.ymthe.2018.07.005","volume":"26","author":"V Golumba-Nagy","year":"2018","unstructured":"Golumba-Nagy V, Kuehle J, Hombach AA, Abken H. CD28-\u03b6 CAR T cells resist TGF-\u03b2 repression through IL-2 signaling, which can be mimicked by an engineered IL-7 autocrine loop. Mol Ther. 2018;26(9):2218\u201330. https:\/\/doi.org\/10.1016\/j.ymthe.2018.07.005.","journal-title":"Mol Ther"},{"issue":"3","key":"1744_CR154","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.994446","volume":"4","author":"M Koneru","year":"2015","unstructured":"Koneru M, Purdon TJ, Spriggs D, Koneru S, Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology. 2015;4(3):e994446. https:\/\/doi.org\/10.4161\/2162402X.2014.994446.","journal-title":"Oncoimmunology"},{"key":"1744_CR155","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.7_suppl.141","author":"OO Yeku","year":"2017","unstructured":"Yeku OO, Purdon T, Spriggs DR, Brentjens RJ. Chimeric antigen receptor (CAR) T cells genetically engineered to deliver IL-12 to the tumor microenvironment in ovarian cancer. J Clin Oncol. 2017. https:\/\/doi.org\/10.1200\/JCO.2017.35.7_suppl.141.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1744_CR156","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, et al. Tumor-targeted t cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119(18):4133\u201341. https:\/\/doi.org\/10.1182\/blood-2011-12-400044.","journal-title":"Blood"},{"key":"1744_CR157","unstructured":"National Cancer Institute, Houston Methodist Cancer Center and Research Institute. Dose escalation\/\u200bdose expansion study of PRGN-3007 UltraCAR-T cells in patients with advanced hematologic and solid tumor malignancies. ClinicalTrials.gov. Identifier: NCT05694364."},{"key":"1744_CR158","unstructured":"Hebei Senlang Biotechnology Inc. Ltd. Anti-PD-L1 armored anti-CD22 CAR-T\/\u200bCAR-TILs targeting patients with solid tumors. ClinicalTrials.gov. Identifier: NCT04556669."},{"key":"1744_CR159","unstructured":"Cancer Hospital, Chinese Academy of Medical Sciences. CD73\/\u200bAXL targeted HypoSti.CAR-T cells in CD73\/\u200bAXL positive advanced\/\u200bmetastatic solid tumors. ClinicalTrials.gov. Identifier: NCT06939270."},{"key":"1744_CR160","unstructured":"Baylor College of Medicine. IC9-GD2-CAR-VZV-CTLs\/\u200brefractory or metastatic GD2-positive sarcoma and neuroblastoma (VEGAS). ClinicalTrials.gov. Identifier: NCT01953900."},{"issue":"14","key":"1744_CR161","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/1078-0432.CCR-16-2138","volume":"23","author":"M Tanaka","year":"2017","unstructured":"Tanaka M, Tashiro H, Omer B, Lapteva N, Ando J, et al. Vaccination targeting native receptors to enhance the function and proliferation of chimeric antigen receptor (CAR)-modified T cells. Clin Cancer Res. 2017;23(14):3499\u2013509. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1744_CR162","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, et al. CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep. 2017;7(1):737. https:\/\/doi.org\/10.1038\/s41598-017-00462-8.","journal-title":"Sci Rep"},{"issue":"10","key":"1744_CR163","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal S, Aznar MA, Rech AJ, Good CR, Kuramitsu S, et al. Deletion of the inhibitory co-receptor CTLA4 enhances and invigorates chimeric antigen receptor T cells. Immunity. 2023;56(10):2388-2407.e9. https:\/\/doi.org\/10.1016\/j.immuni.2023.09.001.","journal-title":"Immunity"},{"issue":"7787","key":"1744_CR164","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","volume":"576","author":"J Wei","year":"2019","unstructured":"Wei J, Long L, Zheng W, Dhungana Y, Lim SA, et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature. 2019;576(7787):471\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1821-z.","journal-title":"Nature"},{"issue":"16_suppl","key":"1744_CR165","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.1089","volume":"42","author":"Y Lin","year":"2024","unstructured":"Lin Y, Yin H, Zhou C, Zhou L, Zeng Y, et al. Phase I clinical trial of MUC1-targeted CAR-T cells with PD-1-knockout in the treatment of advanced breast cancer. J Clin Oncol. 2024;42(16_suppl):1089. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.1089.","journal-title":"J Clin Oncol"},{"key":"1744_CR166","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3389\/fimmu.2020.01109","volume":"11","author":"A Rodriguez-Garcia","year":"2020","unstructured":"Rodriguez-Garcia A, Palazon A, Noguera-Ortega E, Powell DJ Jr, Guedan S. CAR-t cells hit the tumor microenvironment: strategies to overcome tumor escape. Front Immunol. 2020;11:1109. https:\/\/doi.org\/10.3389\/fimmu.2020.01109.","journal-title":"Front Immunol"},{"key":"1744_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2024.100739","volume":"24","author":"C Carcopino","year":"2024","unstructured":"Carcopino C, Erdogan E, Henrich M, Kobold S. Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy. Immuno-Oncology and Technology. 2024;24:100739. https:\/\/doi.org\/10.1016\/j.iotech.2024.100739.","journal-title":"Immuno-Oncology and Technology"},{"key":"1744_CR168","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.omto.2023.08.013","volume":"30","author":"SO Hong","year":"2023","unstructured":"Hong SO, Kim J, Lee S, Shin J, Choi H, et al. Transgenic viral expression of PH-20, IL-12, and sPD1-Fc enhances immune cell infiltration and anti-tumor efficacy of an oncolytic virus. Mol Ther. 2023;30:301\u201315. https:\/\/doi.org\/10.1016\/j.omto.2023.08.013.","journal-title":"Mol Ther"},{"issue":"22","key":"1744_CR169","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-10-0712","volume":"16","author":"W Peng","year":"2010","unstructured":"Peng W, Ye Y, Rabinovich BA, Liu C, Lou Y, et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res. 2010;16(22):5458\u201368. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0712.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1744_CR170","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01355-1","volume":"20","author":"Y Cheng","year":"2021","unstructured":"Cheng Y, Mo F, Li Q, Han X, Shi H, et al. Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin. Mol Cancer. 2021;20(1):62. https:\/\/doi.org\/10.1186\/s12943-021-01355-1.","journal-title":"Mol Cancer"},{"key":"1744_CR171","unstructured":"University of Florida. Phase I study of IL-8 receptor-modified CD70 CAR T cell therapy in CD70+ adult glioblastoma (IMPACT). ClinicalTrials.gov. Identifier: NCT05353530."},{"key":"1744_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106329","volume":"182","author":"SM Sagnella","year":"2022","unstructured":"Sagnella SM, White AL, Yeo D, Saxena P, van Zandwijk N, et al. Locoregional delivery of CAR-T cells in the clinic. Pharmacol Res. 2022;182:106329. https:\/\/doi.org\/10.1016\/j.phrs.2022.106329.","journal-title":"Pharmacol Res"},{"issue":"6","key":"1744_CR173","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1007\/s13346-021-01079-1","volume":"11","author":"OM Turk","year":"2021","unstructured":"Turk OM, Woodall RC, Gutova M, Brown CE, Rockne RC, et al. Delivery strategies for cell-based therapies in the brain: overcoming multiple barriers. Drug Deliv Transl Res. 2021;11(6):2448\u201367. https:\/\/doi.org\/10.1007\/s13346-021-01079-1.","journal-title":"Drug Deliv Transl Res"},{"key":"1744_CR174","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.omto.2020.03.018","volume":"17","author":"A Aalipour","year":"2020","unstructured":"Aalipour A, Le Boeuf F, Tang M, Murty S, Simonetta F, et al. Viral delivery of CAR targets to solid tumors enables effective cell therapy. Mol Ther. 2020;17:232\u201340. https:\/\/doi.org\/10.1016\/j.omto.2020.03.018.","journal-title":"Mol Ther"},{"issue":"7","key":"1744_CR175","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jamaoncol.2021.0168","volume":"7","author":"F Hauth","year":"2021","unstructured":"Hauth F, Ho AY, Ferrone S, Duda DG. Radiotherapy to enhance chimeric antigen receptor T-cell therapeutic efficacy in solid tumors: a narrative review. JAMA Oncol. 2021;7(7):1051\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0168.","journal-title":"JAMA Oncol"},{"key":"1744_CR176","unstructured":"Baylor College of Medicine. Binary oncolytic adenovirus in combination with HER2-specific autologous CAR VST, advanced HER2 positive solid tumors (VISTA). ClinicalTrials.gov. Identifier: NCT03740256."},{"key":"1744_CR177","unstructured":"Sichuan University. Phase I clinical study of \u0391-PD-L1\/\u200bDLL3 CAR-T in patients with R\/\u200bR SCLC. ClinicalTrials.gov. Identifier: NCT06348797."},{"issue":"4","key":"1744_CR178","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","volume":"21","author":"A Page","year":"2024","unstructured":"Page A, Chuvin N, Valladeau-Guilemond J, Depil S. Development of NK cell-based cancer immunotherapies through receptor engineering. Cell Mol Immunol. 2024;21(4):315\u201331. https:\/\/doi.org\/10.1038\/s41423-024-01145-x.","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"1744_CR179","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4049\/jimmunol.1701155","volume":"200","author":"S Srivastava","year":"2018","unstructured":"Srivastava S, Riddell SR. Chimeric antigen receptor T cell therapy: challenges to bench-to-bedside efficacy. J Immunol. 2018;200(2):459\u201368. https:\/\/doi.org\/10.4049\/jimmunol.1701155.","journal-title":"J Immunol"},{"issue":"11","key":"1744_CR180","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1038\/s41587-023-02085-z","volume":"42","author":"JR Hamilton","year":"2024","unstructured":"Hamilton JR, Chen E, Perez BS, Sandoval Espinoza CR, Kang MH, et al. In vivo human T cell engineering with enveloped delivery vehicles. Nat Biotechnol. 2024;42(11):1684\u201392. https:\/\/doi.org\/10.1038\/s41587-023-02085-z.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1744_CR181","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie N, Shen G, Gao W, Huang Z, Huang C, et al. Neoantigens: promising targets for cancer therapy. Sig Transduct Target Ther. 2023;8(1):9. https:\/\/doi.org\/10.1038\/s41392-022-01270-x.","journal-title":"Sig Transduct Target Ther"},{"issue":"6","key":"1744_CR182","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.medj.2024.03.001","volume":"5","author":"J Liu","year":"2024","unstructured":"Liu J, Jiao X, Ma D, Fang Y, Gao Q. CAR-T therapy and targeted treatments: emerging combination strategies in solid tumors. Med. 2024;5(6):530\u201349. https:\/\/doi.org\/10.1016\/j.medj.2024.03.001.","journal-title":"Med"},{"key":"1744_CR183","unstructured":"The Third Affiliated Hospital of Guangzhou Medical University. Pilot study of NKG2D-ligand targeted CAR-NK cells in patients with metastatic solid tumours. ClinicalTrials.gov. Identifier: NCT03415100."},{"key":"1744_CR184","unstructured":"Shanghai East Hospital. Study of anti-5T4 CAR-raNK cell therapy in locally advanced or metastatic solid tumors. ClinicalTrials.gov. Identifier: NCT05137275."},{"key":"1744_CR185","doi-asserted-by":"publisher","first-page":"994532","DOI":"10.3389\/fimmu.2022.994532","volume":"13","author":"R Harari-Steinfeld","year":"2022","unstructured":"Harari-Steinfeld R, Abhinav Ayyadevara VSS, Cuevas L, Marincola F, Roh KH. Standardized in-vitro evaluation of CAR-T cells using acellular artificial target particles. Front Immunol. 2022;13:994532. https:\/\/doi.org\/10.3389\/fimmu.2022.994532.","journal-title":"Front Immunol"},{"issue":"1","key":"1744_CR186","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03335-z","volume":"24","author":"Q Du","year":"2024","unstructured":"Du Q, An Q, Zhang J, Liu C, Hu Q. Unravelling immune microenvironment features underlying tumor progression in the single-cell era. Cancer Cell Int. 2024;24(1):143. https:\/\/doi.org\/10.1186\/s12935-024-03335-z.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1744_CR187","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03272-x","volume":"24","author":"RX Ning","year":"2024","unstructured":"Ning RX, Liu CY, Wang SQ, Li WK, Kong X, et al. Application status and optimization suggestions of tumor organoids and CAR-T cell co-culture models. Cancer Cell Int. 2024;24(1):98. https:\/\/doi.org\/10.1186\/s12935-024-03272-x.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1744_CR188","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0293-7","volume":"5","author":"Q Xue","year":"2017","unstructured":"Xue Q, Bettini E, Paczkowski P, Ng C, Kaiser A, et al. Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response. J Immunother Cancer. 2017;5(1):85. https:\/\/doi.org\/10.1186\/s40425-017-0293-7.","journal-title":"J Immunother Cancer"},{"issue":"2","key":"1744_CR189","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.stem.2024.11.010","volume":"32","author":"M Logun","year":"2025","unstructured":"Logun M, Wang X, Sun Y, Bagley SJ, Li N, et al. Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy. Cell Stem Cell. 2025;32(2):181-190.e4. https:\/\/doi.org\/10.1016\/j.stem.2024.11.010.","journal-title":"Cell Stem Cell"},{"key":"1744_CR190","unstructured":"Lyell Immunopharma Inc. A Study to investigate LYL797 in adults with solid tumors. ClinicalTrials.gov. Identifier: NCT05274451."},{"key":"1744_CR191","unstructured":"A2 Biotherapeutics Inc. A study to evaluate the safety and efficacy of A2B530, a logic-gated CAR T, in participants with solid tumors that express CEA and have lost HLA-A*02 expression (EVEREST-1). ClinicalTrials.gov. Identifier: NCT05736731."},{"key":"1744_CR192","unstructured":"NYU Langone Health. Perlmutter Cancer Center launches logic-gated solid tumor CAR T cell trial. NYUlangone.org. June 29, 2023. https:\/\/nyulangone.org\/news\/perlmutter-cancer-center-launches-logic-gated-solid-tumor-car-t-cell-trial."},{"key":"1744_CR193","unstructured":"National Cancer Institute, Singapore General Hospital. Multi-4SCAR-T therapy targeting breast cancer. ClinicalTrials.gov. Identifier: NCT04430595."},{"key":"1744_CR194","unstructured":"Businesswire. FDA grants regenerative medicine advanced therapy designation for BrainChild Bio\u2019s B7-H3 CAR T-cell therapy for incurable pediatric brain tumors. https:\/\/www.businesswire.com\/news\/home\/20250515031709\/en\/FDA-Grants-Regenerative-Medicine-Advanced-Therapy-Designation-for-BrainChild-Bios-B7-H3-CAR-T-cell-Therapy-for-Incurable-Pediatric-Brain-Tumors."},{"issue":"6","key":"1744_CR195","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi C, Gong J, Li J, Liu D, Qin Y, et al. Claudin18.2-specific CAR t cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. 2022;28(6):1189\u201398. https:\/\/doi.org\/10.1038\/s41591-022-01800-8.","journal-title":"Nat Med"},{"key":"1744_CR196","unstructured":"University of Pennsylvania. CART-EGFR-IL13Ra2 in EGFR amplified recurrent GBM. ClinicalTrials.gov. Identifier: NCT05168423."},{"key":"1744_CR197","unstructured":"Sichuan University. Dual-targeting CLDN18.2 and PD-L1 CAR-T for patients with CLDN18.2-positive advanced solid tumors. ClinicalTrials.gov. Identifier: NCT06084286."},{"issue":"7926","key":"1744_CR198","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","volume":"609","author":"J Zhang","year":"2022","unstructured":"Zhang J, Hu Y, Yang J, Li W, Zhang M, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022;609(7926):369\u201374. https:\/\/doi.org\/10.1038\/s41586-022-05140-y.","journal-title":"Nature"},{"issue":"620","key":"1744_CR199","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh0272","volume":"13","author":"B Prinzing","year":"2021","unstructured":"Prinzing B, Zebley CC, Petersen CT, Fan Y, Anido AA, et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci Transl Med. 2021;13(620):eabh0272. https:\/\/doi.org\/10.1126\/scitranslmed.abh0272.","journal-title":"Sci Transl Med"},{"issue":"9","key":"1744_CR200","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","volume":"18","author":"Z Wang","year":"2021","unstructured":"Wang Z, Li N, Feng K, Chen M, Zhang Y, et al. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. Cell Mol Immunol. 2021;18(9):2188\u201398. https:\/\/doi.org\/10.1038\/s41423-021-00749-x.","journal-title":"Cell Mol Immunol"},{"issue":"6481","key":"1744_CR201","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365","volume":"367","author":"EA Stadtmauer","year":"2020","unstructured":"Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365. https:\/\/doi.org\/10.1126\/science.aba7365.","journal-title":"Science"},{"issue":"1","key":"1744_CR202","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/leu.2016.180","volume":"31","author":"R Monjezi","year":"2017","unstructured":"Monjezi R, Miskey C, Gogishvili T, Schleef M, Schmeer M, et al. Enhanced CAR T-cell engineering using non-viral sleeping beauty transposition from minicircle vectors. Leukemia. 2017;31(1):186\u201394. https:\/\/doi.org\/10.1038\/leu.2016.180.","journal-title":"Leukemia"},{"key":"1744_CR203","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1032397","volume":"13","author":"H Singh","year":"2022","unstructured":"Singh H, Srour SA, Milton DR, McCarty J, Dai C, et al. Sleeping beauty generated CD19 CAR T-cell therapy for advanced B-cell hematological malignancies. Front Immunol. 2022;13:1032397. https:\/\/doi.org\/10.3389\/fimmu.2022.1032397.","journal-title":"Front Immunol"},{"key":"1744_CR204","unstructured":"Chinese PLA General Hospital. Study of CRISPR-Cas9 mediated PD-1 and TCR gene-knocked out mesothelin-directed CAR-T cells in patients with mesothelin positive multiple solid tumors. ClinicalTrials.gov ID NCT03545815."},{"key":"1744_CR205","unstructured":"University of Pennsylvania. NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells). ClinicalTrials.gov. Identifier: NCT03399448."},{"key":"1744_CR206","unstructured":"PACT Pharma Inc. A study of gene edited autologous neoantigen targeted TCR T cells with or without anti-PD-1 in patients with solid tumors. ClinicalTrials.gov. Identifier: NCT03970382."},{"key":"1744_CR207","unstructured":"Poseida Therapeutics Inc. P-MUC1C-ALLO1 allogeneic CAR-T cells in the treatment of subjects with advanced or metastatic solid tumors. ClinicalTrials.gov. Identifier: NCT05239143."},{"key":"1744_CR208","unstructured":"City of Hope Medical Center. CAR T cells after lymphodepletion for the treatment of IL13R\u03b12 positive recurrent or refractory brain tumors in children. ClinicalTrials.gov. Identifier: NCT04510051."},{"issue":"43","key":"1744_CR209","doi-asserted-by":"publisher","first-page":"e2103258","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang M, Lee SH, Kwon M, Byun J, Kim D, et al. Nanocomplex-mediated in vivo programming to chimeric antigen receptor-M1 macrophages for cancer therapy. Adv Mater. 2021;33(43):e2103258. https:\/\/doi.org\/10.1002\/adma.202103258.","journal-title":"Adv Mater"},{"key":"1744_CR210","doi-asserted-by":"publisher","first-page":"105125","DOI":"10.1016\/j.ebiom.2024.105125","volume":"103","author":"AB Carvalho","year":"2024","unstructured":"Carvalho AB, Kasai-Brunswick TH, de Campos Carvalho AC. Advanced cell and gene therapies in cardiology. EBioMedicine. 2024;103:105125. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105125.","journal-title":"EBioMedicine"},{"key":"1744_CR211","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-024-00561-1","volume":"29","author":"X Chen","year":"2024","unstructured":"Chen X, Zhong S, Zhan Y, et al. CRISPR\u2013Cas9 applications in T cells and adoptive T cell therapies. Cell Mol Biol Lett. 2024;29:52. https:\/\/doi.org\/10.1186\/s11658-024-00561-1.","journal-title":"Cell Mol Biol Lett"},{"issue":"11","key":"1744_CR212","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.ccell.2022.10.019","volume":"40","author":"J Zhang","year":"2022","unstructured":"Zhang J, Du B, Liu M. Let\u2019s turn the CAR-T cells ON and OFF precisely. Cancer Cell. 2022;40(11):1264\u20136. https:\/\/doi.org\/10.1016\/j.ccell.2022.10.019.","journal-title":"Cancer Cell"},{"issue":"3","key":"1744_CR213","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41587-019-0344-3","volume":"38","author":"D Ochoa","year":"2020","unstructured":"Ochoa D, Jarnuczak AF, Vi\u00e9itez C, Gehre M, Soucheray M, et al. The functional landscape of the human phosphoproteome. Nat Biotechnol. 2020;38(3):365\u201373. https:\/\/doi.org\/10.1038\/s41587-019-0344-3.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"1744_CR214","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwae018","volume":"11","author":"Z Liao","year":"2024","unstructured":"Liao Z, Jiang J, Wu W, Shi J, Wang Y, et al. Lymph node-biomimetic scaffold boosts CAR-T therapy against solid tumor. Natl Sci Rev. 2024;11(4):nwae018. https:\/\/doi.org\/10.1093\/nsr\/nwae018.","journal-title":"Natl Sci Rev"},{"issue":"1","key":"1744_CR215","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s12951-024-02630-1","volume":"22","author":"MB Khawar","year":"2024","unstructured":"Khawar MB, Afzal A, Si Y, Sun H. Steering the course of CAR T cell therapy with lipid nanoparticles. J Nanobiotechnol. 2024;22(1):380. https:\/\/doi.org\/10.1186\/s12951-024-02630-1.","journal-title":"J Nanobiotechnol"},{"issue":"24","key":"1744_CR216","doi-asserted-by":"publisher","first-page":"00252","DOI":"10.1016\/j.tcb.2024.11.010","volume":"S0962\u20138924","author":"X Wang","year":"2024","unstructured":"Wang X, Fan R, Mu M, Zhou L, Zou B, et al. Harnessing nanoengineered CAR-T cell strategies to advance solid tumor immunotherapy. Trends Cell Biol. 2024;S0962\u20138924(24):00252\u20136. https:\/\/doi.org\/10.1016\/j.tcb.2024.11.010.","journal-title":"Trends Cell Biol"},{"key":"1744_CR217","unstructured":"Mackall, C. GD2 CAR T cells in diffuse intrinsic pontine gliomas (DIPG) & spinal diffuse midline glioma (DMG). ClinicalTrials.gov. Identifier: NCT04196413."},{"key":"1744_CR218","unstructured":"University of Pennsylvania. CART-PSMA-TGF\u03b2RDN cells for castrate-resistant prostate cancer. ClinicalTrials.gov. Identifier: NCT03089203."},{"issue":"6625","key":"1744_CR219","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1126\/science.abq0225","volume":"378","author":"KG Daniels","year":"2022","unstructured":"Daniels KG, Wang S, Simic MS, Bhargava HK, Capponi S, et al. Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning. Science. 2022;378(6625):1194\u2013200. https:\/\/doi.org\/10.1126\/science.abq0225.","journal-title":"Science"},{"key":"1744_CR220","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2022.106084","volume":"150","author":"R Zhang","year":"2022","unstructured":"Zhang R, Han X, Lei Z, Jiang C, Gul I, et al. RCMNet: a deep learning model assists CAR-T therapy for leukemia. Comput Biol Med. 2022;150:106084. https:\/\/doi.org\/10.1016\/j.compbiomed.2022.106084.","journal-title":"Comput Biol Med"},{"key":"1744_CR221","doi-asserted-by":"publisher","DOI":"10.1177\/25151355241305856","author":"M Shahzadi","year":"2024","unstructured":"Shahzadi M, Rafique H, Waheed A, Naz H, Waheed A, et al. Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives. Ther Adv Vaccines Immunother. 2024. https:\/\/doi.org\/10.1177\/25151355241305856.","journal-title":"Ther Adv Vaccines Immunother"},{"issue":"1","key":"1744_CR222","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03765-1","volume":"20","author":"AA Bhat","year":"2022","unstructured":"Bhat AA, Nisar S, Mukherjee S, Saha N, Yarravarapu N, et al. Integration of CRISPR\/Cas9 with artificial intelligence for improved cancer therapeutics. J Transl Med. 2022;20(1):534. https:\/\/doi.org\/10.1186\/s12967-022-03765-1.","journal-title":"J Transl Med"},{"key":"1744_CR223","unstructured":"Bambino Ges\u00f9 Hospital and Research Institute. Anti-GD2 CAR T cells in pediatric patients affected by high risk and\/\u200bor relapsed\/\u200brefractory neuroblastoma or other GD2-positive solid tumors. ClinicalTrials.gov. Identifier: NCT03373097."},{"key":"1744_CR224","unstructured":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors. ClinicalTrials.gov. Identifier: NCT04550663."},{"key":"1744_CR225","unstructured":"Seattle Children\u2019s Hospital. Study of B7-H3-specific CAR T cell locoregional immunotherapy for diffuse intrinsic pontine glioma\/diffuse midline glioma and recurrent or refractory pediatric central nervous system tumors. ClinicalTrials.gov. Identifier: NCT04185038."},{"key":"1744_CR226","unstructured":"Chinese PLA General Hospital. Treatment of relapsed and\/\u200bor chemotherapy refractory advanced malignancies by CART133. ClinicalTrials.gov. Identifier: NCT02541370."},{"issue":"4","key":"1744_CR227","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.100989","volume":"23","author":"G Frumento","year":"2020","unstructured":"Frumento G, Verma K, Croft W, White A, Zuo J, et al. Homeostatic cytokines drive epigenetic reprogramming of activated T cells into a \u2018\u201cNaiveMemory\u201d\u2019 phenotype. iScience. 2020;23(4):100989.","journal-title":"iScience"},{"key":"1744_CR228","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2020.12.004","volume":"500","author":"H Rostamian","year":"2021","unstructured":"Rostamian H, Fallah-Mehrjardi K, Khakpoor-Koosheh M, Pawelek JM, Hadjati J, et al. A metabolic switch to memory CAR T cells: implications for cancer treatment. Cancer Lett. 2021;500:107\u201318. https:\/\/doi.org\/10.1016\/j.canlet.2020.12.004.","journal-title":"Cancer Lett"},{"issue":"8","key":"1744_CR229","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s13238-020-00707-9","volume":"11","author":"Q Liu","year":"2020","unstructured":"Liu Q, Sun Z, Chen L. Memory T cells: strategies for optimizing tumor immunotherapy. Protein Cell. 2020;11(8):549\u201364. https:\/\/doi.org\/10.1007\/s13238-020-00707-9.","journal-title":"Protein Cell"},{"key":"1744_CR230","doi-asserted-by":"publisher","first-page":"878209","DOI":"10.3389\/fimmu.2022.878209","volume":"13","author":"G L\u00f3pez-Cantillo","year":"2022","unstructured":"L\u00f3pez-Cantillo G, Urue\u00f1a C, Camacho BA, Ram\u00edrez-Segura C. CAR-T cell performance: how to improve their persistence? Front Immunol. 2022;13:878209. https:\/\/doi.org\/10.3389\/fimmu.2022.878209.","journal-title":"Front Immunol"},{"key":"1744_CR231","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2020.101435","volume":"49","author":"J Han","year":"2020","unstructured":"Han J, Khatwani N, Searles TG, Turk MJ, Angeles CV. Memory CD8+ T cell responses to cancer. Semin Immunol. 2020;49:101435. https:\/\/doi.org\/10.1016\/j.smim.2020.101435.","journal-title":"Semin Immunol"},{"issue":"12","key":"1744_CR232","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150807","volume":"132","author":"S Arcangeli","year":"2022","unstructured":"Arcangeli S, Bove C, Mezzanotte C, Camisa B, Falcone L, et al. CAR T cell manufacturing from naive\/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J Clin Invest. 2022;132(12):e150807. https:\/\/doi.org\/10.1172\/JCI150807.","journal-title":"J Clin Invest"},{"issue":"10","key":"1744_CR233","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99048","volume":"3","author":"D Wang","year":"2018","unstructured":"Wang D, Aguilar B, Starr R, Alizadeh D, Brito A, et al. Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. JCI Insight. 2018;3(10):e99048. https:\/\/doi.org\/10.1172\/jci.insight.99048.","journal-title":"JCI Insight"},{"issue":"11","key":"1744_CR234","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1158\/2159-8290.CD-17-0263","volume":"7","author":"M Mata","year":"2017","unstructured":"Mata M, Gerken C, Nguyen P, Krenciute G, Spencer DM, et al. Inducible activation of MyD88 and CD40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models. Cancer Discov. 2017;7(11):1306\u201319. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0263.","journal-title":"Cancer Discov"},{"issue":"1","key":"1744_CR235","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41467-024-55751-4","volume":"16","author":"T Zhu","year":"2025","unstructured":"Zhu T, Xiao Y, Chen Z, Ding H, Chen S, et al. Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung. Nat Commun. 2025;16(1):262. https:\/\/doi.org\/10.1038\/s41467-024-55751-4.","journal-title":"Nat Commun"},{"issue":"1","key":"1744_CR236","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-72392-1","volume":"14","author":"AW Li","year":"2024","unstructured":"Li AW, Briones JD, Lu J, Walker Q, Martinez R, et al. Engineering potent chimeric antigen receptor T cells by programming signaling during T-cell activation. Sci Rep. 2024;14(1):21331. https:\/\/doi.org\/10.1038\/s41598-024-72392-1.","journal-title":"Sci Rep"},{"issue":"48","key":"1744_CR237","doi-asserted-by":"publisher","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","volume":"113","author":"LV Hurton","year":"2016","unstructured":"Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci USA. 2016;113(48):E7788-97. https:\/\/doi.org\/10.1073\/pnas.1610544113.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"1744_CR238","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1158\/1078-0432.CCR-22-0721","volume":"28","author":"Q Yang","year":"2022","unstructured":"Yang Q, Hu J, Jia Z, Wang Q, Wang J, et al. Membrane-anchored and tumor-targeted IL-12 (attIL12)-PBMC therapy for osteosarcoma. Clin Cancer Res. 2022;28(17):3862\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0721.","journal-title":"Clin Cancer Res"},{"key":"1744_CR239","unstructured":"University of Louisville Cancer Center. Autologous CAR T-cells targeting the GD2 antigen for lung cancer. ClinicalTrials.gov. Identifier: NCT05620342."},{"issue":"7643","key":"1744_CR240","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543(7643):113\u20137. https:\/\/doi.org\/10.1038\/nature21405.","journal-title":"Nature"},{"issue":"8010","key":"1744_CR241","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan JD, Scheffler CM, Munoz I, Sek K, Lee JN, et al. Foxo1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature. 2024;629(8010):201\u201310. https:\/\/doi.org\/10.1038\/s41586-024-07242-1.","journal-title":"Nature"},{"issue":"8011","key":"1744_CR242","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07300-8","volume":"629","author":"AE Doan","year":"2024","unstructured":"Doan AE, Mueller KP, Chen AY, Rouin GT, Chen Y, et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature. 2024;629(8011):E11. https:\/\/doi.org\/10.1038\/s41586-024-07300-8.","journal-title":"Nature"},{"issue":"4","key":"1744_CR243","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cmet.2022.02.009","volume":"34","author":"L Ye","year":"2022","unstructured":"Ye L, Park JJ, Peng L, Yang Q, Chow RD, et al. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metab. 2022;34(4):595-614.e14. https:\/\/doi.org\/10.1016\/j.cmet.2022.02.009.","journal-title":"Cell Metab"},{"issue":"6","key":"1744_CR244","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1158\/2159-8290.CD-RW2022-054","volume":"12","author":"L Ye","year":"2022","unstructured":"Ye L, Park JJ, Peng L, Yang Q, Chow RD, et al. PRODH2-mediated proline metabolism boosts CAR T-cell effector function. Cancer Discov. 2022;12(6):1405. https:\/\/doi.org\/10.1158\/2159-8290.CD-RW2022-054.","journal-title":"Cancer Discov"},{"key":"1744_CR245","doi-asserted-by":"publisher","first-page":"1113882","DOI":"10.3389\/fimmu.2023.1113882","volume":"14","author":"A Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, Mardi A, Aghebati-Maleki A, et al. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front Immunol. 2023;14:1113882. https:\/\/doi.org\/10.3389\/fimmu.2023.1113882. (Mar 20;).","journal-title":"Front Immunol"},{"issue":"1","key":"1744_CR246","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","volume":"22","author":"KM Maalej","year":"2023","unstructured":"Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20. https:\/\/doi.org\/10.1186\/s12943-023-01723-z.","journal-title":"Mol Cancer"},{"issue":"9","key":"1744_CR247","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","volume":"9","author":"J Hartmann","year":"2017","unstructured":"Hartmann J, Sch\u00fc\u00dfler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017;9(9):1183\u201397. https:\/\/doi.org\/10.15252\/emmm.201607485.","journal-title":"EMBO Mol Med"},{"issue":"8","key":"1744_CR248","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj6251","volume":"10","author":"L Lu","year":"2024","unstructured":"Lu L, Xie M, Yang B, Zhao WB, Cao J. Enhancing the safety of CAR-T cell therapy: synthetic genetic switch for spatiotemporal control. Sci Adv. 2024;10(8):eadj6251. https:\/\/doi.org\/10.1126\/sciadv.adj6251.","journal-title":"Sci Adv"},{"issue":"4","key":"1744_CR249","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38(4):473\u201388. https:\/\/doi.org\/10.1016\/j.ccell.2020.07.005.","journal-title":"Cancer Cell"},{"key":"1744_CR250","unstructured":"City of Hope Medical Center. Genetically modified T-cells in treating patients with recurrent or refractory malignant glioma. ClinicalTrials.gov. Identifier: NCT02208362."},{"key":"1744_CR251","unstructured":"City of Hope Medical Center. IL13Ra2-CAR T cells with or without nivolumab and ipilimumab in treating patients with GBM. ClinicalTrials.gov. Identifier: NCT04003649."},{"issue":"11","key":"1744_CR252","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen A, Haanen JBAG, Koenecke C, Alsdorf W, Wagner-Drouet E, et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat Med. 2023;29(11):2844\u201353. https:\/\/doi.org\/10.1038\/s41591-023-02612-0.","journal-title":"Nat Med"},{"key":"1744_CR253","unstructured":"City of Hope Medical Center. HER2-CAR T cells in treating patients with recurrent brain or leptomeningeal metastases. ClinicalTrials.gov. Identifier: NCT03696030."},{"key":"1744_CR254","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102475","volume":"60","author":"SY Ahn","year":"2025","unstructured":"Ahn SY, Vo MC, Nguyen VT, Tran VD, Duc TN, et al. Expanded and activated marrow-infiltrating lymphocytes exhibit potent antimyeloma activity against autologous multiple myeloma cells. Transl Oncol. 2025;60:102475. https:\/\/doi.org\/10.1016\/j.tranon.2025.102475.","journal-title":"Transl Oncol"},{"key":"1744_CR255","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-188428","volume":"142","author":"MC Vo","year":"2023","unstructured":"Vo MC, Jung SH, Nguyen VT, Tran VD, Kim SK, et al. Anti-BCMA dual epitope-binding CAR-marrow infiltrating lymphocytes (MILs) could offer a potent innovative immunotherapeutic tool against multiple myeloma. Blood. 2023;142:6811. https:\/\/doi.org\/10.1182\/blood-2023-188428.","journal-title":"Blood"},{"issue":"7","key":"1744_CR256","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41423-021-00686-9","volume":"18","author":"JL Thangaraj","year":"2021","unstructured":"Thangaraj JL, Ahn SY, Jung SH, Vo MC, Chu TH, et al. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model. Cell Mol Immunol. 2021;18(7):1652\u201361. https:\/\/doi.org\/10.1038\/s41423-021-00686-9.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"1744_CR257","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41423-021-00666-z","volume":"18","author":"MC Vo","year":"2021","unstructured":"Vo MC, Ahn SY, Chu TH, Uthaman S, Pillarisetti S, et al. A combination of immunoadjuvant nanocomplexes and dendritic cell vaccines in the presence of immune checkpoint blockade for effective cancer immunotherapy. Cell Mol Immunol. 2021;18(6):1599\u2013601. https:\/\/doi.org\/10.1038\/s41423-021-00666-z.","journal-title":"Cell Mol Immunol"},{"key":"1744_CR258","unstructured":"Zhujiang Hospital, Southern Medical University (China). Anti-GD2 4th generation CART cells targeting refractory and\/\u200bor recurrent neuroblastoma (4SCAR-GD2). ClinicalTrials.gov. Identifier: NCT02765243."},{"issue":"10","key":"1744_CR259","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/d41573-023-00140-7","volume":"22","author":"M Verma","year":"2023","unstructured":"Verma M, Obergfell K, Topp S, Panier V, Wu J. The next-generation CAR-T therapy landscape. Nat Rev Drug Discov. 2023;22(10):776\u20137. https:\/\/doi.org\/10.1038\/d41573-023-00140-7.","journal-title":"Nat Rev Drug Discov"},{"key":"1744_CR260","unstructured":"U.S. Food and Drug Administration. Cellular & gene therapy guidances. (2025) https:\/\/www.fda.gov\/vaccines-blood-biologics\/biologics-guidances\/cellular-gene-therapy-guidances."},{"issue":"11","key":"1744_CR261","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1038\/s41591-023-02623-x","volume":"29","author":"A Chehrazi-Raffle","year":"2023","unstructured":"Chehrazi-Raffle A, Budde LE, Pal SK. Boosting CAR t cells with anti-tumor mRNA vaccines. Nat Med. 2023;29(11):2711\u20132. https:\/\/doi.org\/10.1038\/s41591-023-02623-x.","journal-title":"Nat Med"},{"issue":"21","key":"1744_CR262","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2221116120","volume":"120","author":"Y Pan","year":"2023","unstructured":"Pan Y, Phillips JW, Zhang BD, Noguchi M, Kutschera E, et al. IRIS: discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing. Proc Natl Acad Sci U S A. 2023;120(21):e2221116120. https:\/\/doi.org\/10.1073\/pnas.2221116120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1744_CR263","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2147\/BTT.S291768","volume":"15","author":"ER Hawkins","year":"2021","unstructured":"Hawkins ER, D\u2019Souza RR, Klampatsa A. Armored CAR T-cells: the next chapter in T-cell cancer immunotherapy. Biologics. 2021;15:95\u2013105. https:\/\/doi.org\/10.2147\/BTT.S291768.","journal-title":"Biologics"},{"issue":"11","key":"1744_CR264","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","volume":"40","author":"HS Li","year":"2022","unstructured":"Li HS, Wong NM, Tague E, Ngo JT, Khalil AS, et al. High-performance multiplex drug-gated CAR circuits. Cancer Cell. 2022;40(11):1294-1305.e4. https:\/\/doi.org\/10.1016\/j.ccell.2022.08.008.","journal-title":"Cancer Cell"},{"issue":"3","key":"1744_CR265","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41591-025-03510-3","volume":"31","author":"R Chok","year":"2025","unstructured":"Chok R, Ramakrishna S. Allogeneic approach unlocks CAR t cell benefits in solid tumors. Nat Med. 2025;31(3):733\u20134. https:\/\/doi.org\/10.1038\/s41591-025-03510-3.","journal-title":"Nat Med"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01744-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01744-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01744-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:11:30Z","timestamp":1761847890000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01744-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":265,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1744"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01744-9","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"8 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The manuscript has not been previously published and is not under consideration elsewhere. All authors have reviewed the final version and consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No artificial intelligence tools were used in the preparation or editing of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of AI"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"91"}}